Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast Dual CAR-T in CD19+ R/R B-NHL
NCT04877080Phase 1Withdrawn
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of GC012 in B-cell non-Hodgkin lymphoma. Primary endpoint: Incidence of Adverse Events at 24 weeks. Planned start May 2021; status: withdrawn.
02
Drugs
GC012
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04877080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877080.